Method to determine the degree and stability of blood glucose control in patients with diabetes mellitus via the creation and continuous update of new statistical indicators in blood glucose monitors or free standing computers

• US 20070010950A1
• Filed: 12/03/2005
• Published: 01/11/2007
• Est. Priority Date: 12/03/2004
• Status: Abandoned Application

• Current Assignee: Roche Diabetes Care Inc. (Roche Holding AG)
• Original Assignee: Roche Diabetes Care Inc. (Roche Holding AG)
• Inventors: Abensour, Daniel, Harrell, R.
• Application Number:
  US11/293,534
• Publication Number:
  US 20070010950A1
• Time in Patent Office: Days
• US Class Current: 702/19
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement

Abstract

Microvascular complications of diabetes mellitus are closely related to blood glucose levels and fluctuations. The Glycostator statistical package was created to allow patients and health care providers simple access to “glycemic indicators” which permit a “snapshot view” of the effectiveness of the patient'"'"'s diabetes management program. Glycostator functions provide a simple way of enhancing the information already provided by home blood glucose monitoring devices. To this end, a set of new indices, including one called the Virtual A1c, are computed in a recursive fashion from blood glucose test results to provide a more meaningful day-to-day assessment of glycemic control. All indices can be made available at the meter user interface on request. The displayed indices allow patients to improve glycemic control by identifying problems with blood glucose control and lability that are less easily recognized in traditional blood glucose meter statistical packages. Virtual A1c emulates hemoglobin A1c continuously and provides better day-to-day assessment of long term glycemic control than does the traditional average blood glucose report. The method for computing each of these indices, including the Virtual A1c, allows for their implementation in commercial blood glucose monitors.

Claims

1. A method for enhanced statistical analysis of blood glucose monitoring data called “

Glycostator”

consisting of 3 new parameters of diabetes control;

(1) Time Averaged Glucose (TAG), (2) Virtual A1c (A1c) and (3) Lability Factor (LF).

2. A method for calculation of the parameter from claim (1) called “

Time Averaged Glucose (TAG),”

consisting of a trapezoidal approximation of the integral of blood glucose concentration over time and yielding a more accurate estimate of glucose control than the traditionally employed running average blood glucose feature employed on most blood glucose devices in the United States.

3. A method for calculation of the parameter from claim (1) called “

Virtual A1c (VA1c),”

derived from TAG and emulating the commonly used laboratory test called hemoglobin A1c, with the capability of providing patients, health care providers and health plan managers a time normalized “

snapshot view”

of diabetic blood glucose control without having to perform the laboratory based hemoglobin A1c test, currently considered the gold standard for assessment of diabetes control and eliminating some of the drawbacks of this test.

4. A method for calculation of the new parameter from claim (1) called “

ability Factor (LF)”

derived from TAG and based on the concept of coefficient of variation for blood glucose, representing the variability of blood glucose values and indirectly assessing the reliability of VA1c in addition to promoting the conclusions of the recent research which suggests that glycemic variability may be an independent risk factor for the development of microvascular complications in diabetes mellitus.

6. A method for directly computing the Time Averaged Glucose, Virtual A1c and Lability Factor components of claim 1 on a general purpose computer or on a personal data assistant (PDA) platform, including the steps of:

downloading the test data from the blood glucose meter on the general purpose computer or on the PDA, data including for each test;

date, time and test values;

selecting a time period to cover the assessment of the diabetes management;

approximating the continuous function of blood glucose vs time with the discrete sequence of time stamped test results;

using this timed sequence to compute the Time Averaged Glucose by approximating the average of the continuous function of blood glucose vs time over the assessment period, this approximation consisting in using a numerical analysis approach to determine the numerical value of the integral of the function blood glucose vs time over the assessment period;

using the weighing of each test result by a coefficient between 0 and 1 with the curvature of the above sequence simulating the aging of the red cells and their progressive decay and allowing the computation of the Virtual A1c parameter;

computing the ratio of the standard deviation of the original test value sequence to the Time Averaged Glucose previously determined to provide the Lability Factor.

5. A method for iteratively calculating the Time Averaged Glucose, Virtual A1c and Lability Factor over a specific period of time using recursive formulas that can easily be implemented on existing platforms (blood glucose monitors already in the marketplace) with minimal requirements for processing and memory.